作者: K. Stephen Suh , Takemi Tanaka , Sreeja Sarojini , Ginah Nightingale , Rajendra Gharbaran
DOI: 10.1016/J.CRITREVONC.2013.02.005
关键词:
摘要: The ubiquitin-proteasome system (UPS) maintains the integrity of cellular processes by controlling protein degradation pathways. role UPS in proliferation, cell cycle, differentiation, DNA repair, folding, and apoptosis is well documented, a wide range activities these signaling pathways can be manipulated inhibitors, which include many anti-cancer agents. Naturally occurring synthetic drugs designed to target are currently used for hematological cancers, including lymphoma. These largely interfere with E1 E2 regions 26S proteasome, blocking proteasomal activity promoting enhancing extrinsic (death receptors, Trail, Fas) intrinsic (caspases, Bax, Bcl2, p53, nuclear factor-kappa B, p27) death programs. This review focuses on recent clinical developments concerning that affected down-regulation activities, apoptotic mechanisms promoted this class treat